- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 | 2 | GlobeNewswire (USA) | ||
| 04.02. | B.Riley reiterates Buy rating on Journey Medical stock, maintains $12 target | 2 | Investing.com | ||
| 08.01. | Journey Medical (DERM) Publishes Positive Emrosi Phase 1 Microbiome Data | 2 | Insider Monkey | ||
| 10.12.25 | Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology | 3 | GlobeNewswire (USA) | ||
| 12.11.25 | Earnings Call: Journey Medical meldet Umsatzwachstum für Q3 2025 und stellt positives EBITDA in Aussicht | 6 | Investing.com Deutsch | ||
| 12.11.25 | Journey Medical GAAP EPS of -$0.09, revenue of $17.6M | 2 | Seeking Alpha | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 12.11.25 | Journey Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 245 | GlobeNewswire (Europe) | Third quarter 2025 net revenues were $17.6 million Emrosi total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today... ► Artikel lesen | |
| 12.11.25 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.11.25 | Insights into Journey Medical's Upcoming Earnings | 13 | Benzinga.com | ||
| 05.11.25 | Journey Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025 | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Journey Medical Reports Pooled Phase 3 Data For Emrosi In Rosacea | 2 | RTTNews | ||
| 24.10.25 | Journey Medical's Emrosi shows superior efficacy for rosacea | 1 | Investing.com | ||
| 26.09.25 | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 12.08.25 | Journey Medical Corporation Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights | 629 | GlobeNewswire (Europe) | Second quarter 2025 revenues were $15.0 million Emrosi net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June... ► Artikel lesen | |
| 14.05.25 | Journey Medical Corporation Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | 176 | GlobeNewswire (Europe) | Revenue for the First Quarter Ended March 31, 2025 was $13.1 million Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) Commercial Launch Off to a Strong Start, Initial Prescriptions... ► Artikel lesen | |
| 01.04.25 | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 255 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
| 26.03.25 | Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights | 715 | GlobeNewswire (Europe) | FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,315 | +0,15 % | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfizer | 3 Charts in 3x33 Sekunden - Heute mit DAX, Palo Alto und Pfize ► Artikel lesen | |
| GILEAD SCIENCES | 118,32 | -0,12 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ELI LILLY | 782,30 | -0,29 % | Stammzelltherapien erreichen den Markt - Mesoblast neben Eli Lilly und Novartis im Fokus | ||
| VERTEX PHARMACEUTICALS | 394,50 | +0,38 % | VERTEX PHARMACEUTICALS INC in ruhiger Marktstruktur | ||
| EYEPOINT | 11,290 | 0,00 % | EyePoint sues Ocular over claims related to lead asset | ||
| LIGAND PHARMACEUTICALS | 177,00 | -0,56 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 156,75 | +0,29 % | Jazz Pharmaceuticals Plc Q4 Profit Climbs | WASHINGTON (dpa-AFX) - Jazz Pharmaceuticals plc (JAZZ) released earnings for its fourth quarter that Increases, from the same period last yearThe company's earnings totaled $203.45 million,... ► Artikel lesen | |
| UNITED THERAPEUTICS | 457,20 | +0,75 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| OPKO HEALTH | 0,999 | +0,95 % | OPKO Health beruft Subbarao V. Uppaluri in den Verwaltungsrat | ||
| ROYALTY PHARMA | 38,800 | -1,05 % | Royalty Pharma plc: Royalty Pharma Announces Expansion of Leadership Team | NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President,... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 19,265 | -2,28 % | CATALYST PHARMACEUTICALS, INC. - 8-K, Current Report | ||
| BRIDGEBIO PHARMA | 60,14 | +1,38 % | BridgeBio Pharma, Inc.: BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ||
| TG THERAPEUTICS | 25,990 | +0,08 % | TG Therapeutics, Inc.: TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million | NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. ("TG" or "the Company"), (NASDAQ: TGTX), today announced that it has entered into a new five-year, $750 million senior secured credit... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 7,850 | +4,67 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit | ||
| SOLIGENIX | 1,210 | -0,82 % | SOLIGENIX, INC.: Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford) | Study results support advancing SGX945 in this difficult-to-treat orphan disease
Results suggest potential durability of response for maintenance therapy
PRINCETON, N.J., Dec. 18... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell -4,59 % bei einem Aktienkurs von 6,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.